. Author manuscript; available in PMC: 2022 Feb 17.

Published in final edited form as: Allergol Immunopathol (Madr). 2021 Jan 2;49(1):153–158. doi: 10.15586/aei.v49i1.12

Table 1.

Proposal for albuterol administration in patients with viral bronchiolitis, at least on a therapeutic trial basis.

	Pros for use of albuterol	Cons for use of albuterol
Viral agent	RV^{12,14,19–21}	RSV
RSV genotype	RSV genotype ON1 and BA³⁷	RSV genotype NA1
Seasonal period	Nonpeak months or non-RSV-predominant months^23,34	Peak months for RSV
Nasal microbiome	Hemophilus influenzae ^15,16	Streptococcus pneumoniae
Clinical presentation	Older age (>6–12 months)^25–29	Younger
	Wheezing^30,31	Crackles
	Atopic dermatitis^34,35	-
	History of asthma in first-degree family^30,35	-

RV: rhinovirus; IL: interleukine; IFNγ: interferon gamma; IFNL 1R: interferon lambda receptor 1; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cell; RSV: respiratory syncytial virus.